Background and Objectives: Pancreatic neuroendocrine tumors (pNETs) are relatively rare and consist of 2% of the all pancreatic tumors. Although some of pNETs have a benign, nonprogressive course, some may be progressive and result with metastasis. We aimed to estimate the grade of pNETs by using artificial intelligence (AI) via deep learning (DL) algorithms as indexing to cyto/histopathological classification according to the World Health Organization 2017. Methods: A total of 803 EUS images were collected from 44 patients who had a cyto/histo-pathologically confirmed diagnosis with EUS fine-needle aspiration or biopsy (FNA/B). First, raw EUS images were prepared for processing by AI via DL algorithms, and convolutional neural networks were utilized to train the machine to predict the grades from EUS images. IBM SPSS 25.0 program was used for statistical analyses. Results: Thirty of the 44 patients (68%) were female, with a median age of 61 (range, 16–80) years. pNETs were mostly located in the pancreatic head: 24 cases (55%). Location was the neck in 3 (7%), body in 10 (22%), and tail in 7 (16%) patients. According to EUS-FNA/B results, 27 patients were grade 1 (G1) (61%); 12, grade 2 (G2) (27%); and 5, grade 3 (G3) (12%). In reference to the performance of AI for predicting the pathological grade, sensitivity was 94.29%; specificity, 97.14%; and accuracy, 96.19%. When the patient groups were subanalyzed as G1, G2, and G3 by the AI model to predict the pathological grade, the accuracy was as follows: for G1, 93.15%; for G2, 91.61%; and for G3, 98.05%. Conclusions: This pilot study suggests that pNET grade prediction can be reliably done on EUS images using AI-based technology.
1 December 2011 in Turkish Journal of Gastroenterology
Owing to its high efficacy, ease of use, perfect adaptation and low complication profile, it is suggested that the triple therapy combination consisting of levofloxacin, amoxicillin and proton pump inhibitor may be an alternative for the first-line and second-line treatment of Helicobacter pylori. The aim of this study is to evaluate the efficacy of the triple therapy regimen containing two different doses of levofloxacin in the first-line eradication treatment. 110 naïve patients with anti Helicobacter pylori treatment indications according to Maastricht III Consensus Report were included to the study. Patients were randomized into two groups as the patients treated with a levofloxacin (500 mg o.i.d), amoxicillin (1 g b.i.d) and proton pump inhibitor (b.i.d) combination for 10 days (Group 1, n=60) and patients treated with a levofloxacin (500 mg b.i.d), amoxicillin (1 g b.i.d) and proton pump inhibitor (b.i.d) combination for 10 days (Group 2, n=50). Eradication rate was assessed at the 6th week of therapy just subsequent to termination of treatment. 110 treatment-naïve patients (60 female, mean age: 44.1±14.7 years) were randomized and all patients completed the study. Helicobacter pylori eradication of the Group 1 was 60% and in Group 2 was 72.7%. The difference between the two groups was not statistically significant (p=0.427). None of patients experienced severe complication that would lead to discontinuation of therapy. It is observed that the efficacy of the triple therapy combination containing levofloxacin is not within acceptable limits for the first-line Helicobacter pylori eradication.